Paul Smith, Ph.D.

Paul Smith, Ph.D.

Position: Vice President, Discovery Biology

Dr. Smith joined Connect in September 2021 and has more than 15 years of drug discovery experience primarily focused on the treatment of inflammatory and autoimmune diseases. Prior to joining Connect, Dr. Smith was Senior Director of Inflammation and Autoimmunity at Incyte Corporation where he established the discovery research team including the FDA approvals of Opzelura™ (ruxolitinib cream) for atopic dermatitis and Jakafi™ (oral ruxolitinib) for acute and chronic graft versus host disease. Prior to that role, Dr. Smith was the global research lead for Gilenya™ (fingolimod), the first regulatory approved sphingosine 1-phosphate (S1P) receptor modulator and Kesimpta™ (ofatumumab) a differentiated anti-CD20 therapy for the treatment of multiple sclerosis. He was also Director of Pharmacology at Merck Serono responsible for preclinical inflammation and biomarker discovery and Senior Scientist at UCB focusing on novel biologics-based treatment strategies for inflammatory diseases. Dr. Smith is an inventor on fifteen issued or pending patents. He received his Ph.D. in Immunology and Neuroscience at Imperial College London, UK and a B.Sc. in Pharmacology from the University of Bath, UK.